APO Research
Talk to an analyst

APO RESEARCH · REPORT

DTIs for Injection

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global DTIs for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025198 pages

Choose your research edition.

Industry ResearchDTIs for Injection Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal DTIs for Injection Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal DTIs for Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal DTIs for Injection Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal DTIs for Injection Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global DTIs for Injection market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for DTIs for Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of DTIs for Injection include Yangtze River Pharmaceutical, Beijing SL Pharmaceutical, CSPC Ouyi Pharmaceutical, Lunan Pharmaceutical, BrightGene, The Medicines Company, Teva Pharmaceutical, Sandoz and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global DTIs for Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of DTIs for Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents DTIs for Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the DTIs for Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

DTIs for Injection Segment by Company

Yangtze River Pharmaceutical

Beijing SL Pharmaceutical

CSPC Ouyi Pharmaceutical

Lunan Pharmaceutical

BrightGene

The Medicines Company

Teva Pharmaceutical

Sandoz

Pfizer

Mitsubishi Tanabe Pharma

GlaxoSmithKline

Eugia Pharma

Dr.Reddy's Laboratories

Aurobindo Pharma

Apotex

Accord Healthcare

DTIs for Injection Segment by Type

Argatroban

Bivalirudin

Other

DTIs for Injection Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

DTIs for Injection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global DTIs for Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of DTIs for Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of DTIs for Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the DTIs for Injection market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of DTIs for Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of DTIs for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of DTIs for Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. DTIs for Injection Industry Trends Table 2. DTIs for Injection Industry Drivers Table 3. DTIs for Injection Industry Opportunities and Challenges Table 4. DTIs for Injection Industry Restraints Table 5. Global DTIs for Injection Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global DTIs for Injection Revenue Market Share by Manufacturers (2021-2026) Table 7. Global DTIs for Injection Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global DTIs for Injection Sales Market Share by Manufacturers Table 9. Global DTIs for Injection Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global DTIs for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global DTIs for Injection Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global DTIs for Injection Manufacturers, Product Type & Application Table 13. Global DTIs for Injection Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global DTIs for Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Argatroban Table 17. Major Manufacturers of Bivalirudin Table 18. Major Manufacturers of Other Table 19. Global DTIs for Injection Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global DTIs for Injection Sales by Type (2021-2026) & (K Units) Table 21. Global DTIs for Injection Sales by Type (2027-2032) & (K Units) Table 22. Global DTIs for Injection Sales Market Share by Type (2021-2026) Table 23. Global DTIs for Injection Sales Market Share by Type (2027-2032) Table 24. Global DTIs for Injection Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global DTIs for Injection Revenue by Type (2021-2026) & (K Units) Table 26. Global DTIs for Injection Revenue by Type (2027-2032) & (K Units) Table 27. Global DTIs for Injection Revenue Market Share by Type (2021-2026) Table 28. Global DTIs for Injection Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Pulmonary Embolism Table 30. Major Manufacturers of Deep Vein Thrombosis Table 31. Major Manufacturers of Atrial Fibrillation Table 32. Major Manufacturers of Other Table 33. Global DTIs for Injection Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global DTIs for Injection Sales by Application (2021-2026) & (K Units) Table 35. Global DTIs for Injection Sales by Application (2027-2032) & (K Units) Table 36. Global DTIs for Injection Sales Market Share by Application (2021-2026) Table 37. Global DTIs for Injection Sales Market Share by Application (2027-2032) Table 38. Global DTIs for Injection Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global DTIs for Injection Revenue by Application (2021-2026) & (K Units) Table 40. Global DTIs for Injection Revenue by Application (2027-2032) & (K Units) Table 41. Global DTIs for Injection Revenue Market Share by Application (2021-2026) Table 42. Global DTIs for Injection Revenue Market Share by Application (2027-2032) Table 43. Global DTIs for Injection Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global DTIs for Injection Sales by Region (2021-2026) & (K Units) Table 45. Global DTIs for Injection Sales Market Share by Region (2021-2026) Table 46. Global DTIs for Injection Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global DTIs for Injection Sales Forecasted Market Share by Region (2027-2032) Table 48. North America DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America DTIs for Injection Sales by Country (2021-2026) & (K Units) Table 50. North America DTIs for Injection Sales by Country (2027-2032) & (K Units) Table 51. Europe DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe DTIs for Injection Sales by Country (2021-2026) & (K Units) Table 53. Europe DTIs for Injection Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific DTIs for Injection Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific DTIs for Injection Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa DTIs for Injection Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa DTIs for Injection Sales by Country (2027-2032) & (K Units) Table 60. Global DTIs for Injection Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global DTIs for Injection Revenue by Region (2021-2026) & (US$ Million) Table 62. Global DTIs for Injection Revenue by Region (2027-2032) & (US$ Million) Table 63. Global DTIs for Injection Revenue Market Share by Region (2021-2026) Table 64. Global DTIs for Injection Revenue Market Share by Region (2027-2032) Table 65. Yangtze River Pharmaceutical Company Information Table 66. Yangtze River Pharmaceutical Business Overview Table 67. Yangtze River Pharmaceutical DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Yangtze River Pharmaceutical DTIs for Injection Product Portfolio Table 69. Yangtze River Pharmaceutical Recent Development Table 70. Beijing SL Pharmaceutical Company Information Table 71. Beijing SL Pharmaceutical Business Overview Table 72. Beijing SL Pharmaceutical DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Beijing SL Pharmaceutical DTIs for Injection Product Portfolio Table 74. Beijing SL Pharmaceutical Recent Development Table 75. CSPC Ouyi Pharmaceutical Company Information Table 76. CSPC Ouyi Pharmaceutical Business Overview Table 77. CSPC Ouyi Pharmaceutical DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. CSPC Ouyi Pharmaceutical DTIs for Injection Product Portfolio Table 79. CSPC Ouyi Pharmaceutical Recent Development Table 80. Lunan Pharmaceutical Company Information Table 81. Lunan Pharmaceutical Business Overview Table 82. Lunan Pharmaceutical DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Lunan Pharmaceutical DTIs for Injection Product Portfolio Table 84. Lunan Pharmaceutical Recent Development Table 85. BrightGene Company Information Table 86. BrightGene Business Overview Table 87. BrightGene DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. BrightGene DTIs for Injection Product Portfolio Table 89. BrightGene Recent Development Table 90. The Medicines Company Company Information Table 91. The Medicines Company Business Overview Table 92. The Medicines Company DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. The Medicines Company DTIs for Injection Product Portfolio Table 94. The Medicines Company Recent Development Table 95. Teva Pharmaceutical Company Information Table 96. Teva Pharmaceutical Business Overview Table 97. Teva Pharmaceutical DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Teva Pharmaceutical DTIs for Injection Product Portfolio Table 99. Teva Pharmaceutical Recent Development Table 100. Sandoz Company Information Table 101. Sandoz Business Overview Table 102. Sandoz DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Sandoz DTIs for Injection Product Portfolio Table 104. Sandoz Recent Development Table 105. Pfizer Company Information Table 106. Pfizer Business Overview Table 107. Pfizer DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Pfizer DTIs for Injection Product Portfolio Table 109. Pfizer Recent Development Table 110. Mitsubishi Tanabe Pharma Company Information Table 111. Mitsubishi Tanabe Pharma Business Overview Table 112. Mitsubishi Tanabe Pharma DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Mitsubishi Tanabe Pharma DTIs for Injection Product Portfolio Table 114. Mitsubishi Tanabe Pharma Recent Development Table 115. GlaxoSmithKline Company Information Table 116. GlaxoSmithKline Business Overview Table 117. GlaxoSmithKline DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. GlaxoSmithKline DTIs for Injection Product Portfolio Table 119. GlaxoSmithKline Recent Development Table 120. Eugia Pharma Company Information Table 121. Eugia Pharma Business Overview Table 122. Eugia Pharma DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Eugia Pharma DTIs for Injection Product Portfolio Table 124. Eugia Pharma Recent Development Table 125. Dr.Reddy's Laboratories Company Information Table 126. Dr.Reddy's Laboratories Business Overview Table 127. Dr.Reddy's Laboratories DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Dr.Reddy's Laboratories DTIs for Injection Product Portfolio Table 129. Dr.Reddy's Laboratories Recent Development Table 130. Aurobindo Pharma Company Information Table 131. Aurobindo Pharma Business Overview Table 132. Aurobindo Pharma DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Aurobindo Pharma DTIs for Injection Product Portfolio Table 134. Aurobindo Pharma Recent Development Table 135. Apotex Company Information Table 136. Apotex Business Overview Table 137. Apotex DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Apotex DTIs for Injection Product Portfolio Table 139. Apotex Recent Development Table 140. Accord Healthcare Company Information Table 141. Accord Healthcare Business Overview Table 142. Accord Healthcare DTIs for Injection Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Accord Healthcare DTIs for Injection Product Portfolio Table 144. Accord Healthcare Recent Development Table 145. Key Raw Materials Table 146. Raw Materials Key Suppliers Table 147. DTIs for Injection Distributors List Table 148. DTIs for Injection Customers List Table 149. Research Programs/Design for This Report Table 150. Authors List of This Report Table 151. Secondary Sources Table 152. Primary Sources List of Figures Figure 1. DTIs for Injection Product Image Figure 2. Global DTIs for Injection Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global DTIs for Injection Market Size (2021-2032) & (US$ Million) Figure 4. Global DTIs for Injection Sales (2021-2032) & (K Units) Figure 5. Global DTIs for Injection Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 DTIs for Injection Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Argatroban Image Figure 9. Bivalirudin Image Figure 10. Other Image Figure 11. Global DTIs for Injection Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global DTIs for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global DTIs for Injection Sales Market Share by Type (2021-2032) Figure 14. Global DTIs for Injection Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global DTIs for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global DTIs for Injection Revenue Market Share by Type (2021-2032) Figure 17. Pulmonary Embolism Image Figure 18. Deep Vein Thrombosis Image Figure 19. Atrial Fibrillation Image Figure 20. Other Image Figure 21. Global DTIs for Injection Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global DTIs for Injection Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global DTIs for Injection Sales Market Share by Application (2021-2032) Figure 24. Global DTIs for Injection Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global DTIs for Injection Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global DTIs for Injection Revenue Market Share by Application (2021-2032) Figure 27. North America DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America DTIs for Injection Sales Market Share by Country (2021-2032) Figure 29. U.S. DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe DTIs for Injection Sales Market Share by Country (2021-2032) Figure 34. Germany DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific DTIs for Injection Sales Market Share by Country (2021-2032) Figure 41. China DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa DTIs for Injection Sales Market Share by Country (2021-2032) Figure 49. Brazil DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile DTIs for Injection Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global DTIs for Injection Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global DTIs for Injection Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America DTIs for Injection Revenue (2021-2032) & (US$ Million) Figure 60. North America DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe DTIs for Injection Revenue (2021-2032) & (US$ Million) Figure 62. Europe DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific DTIs for Injection Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa DTIs for Injection Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. DTIs for Injection Value Chain Figure 68. Manufacturing Cost Structure Figure 69. DTIs for Injection Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Argatroban
  • Bivalirudin
  • Other
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Yangtze River Pharmaceutical
  • Beijing SL Pharmaceutical
  • CSPC Ouyi Pharmaceutical
  • Lunan Pharmaceutical
  • BrightGene
  • The Medicines Company
  • Teva Pharmaceutical
  • Sandoz
  • Pfizer
  • Mitsubishi Tanabe Pharma
  • GlaxoSmithKline
  • Eugia Pharma
  • Dr.Reddy's Laboratories
  • Aurobindo Pharma
  • Apotex
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global DTIs for Injection Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global DTIs for Injection Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global DTIs for Injection Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global DTIs for Injection Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global DTIs for Injection Market Dynamics
  1. 2.1 DTIs for Injection Industry Trends
  2. 2.2 DTIs for Injection Industry Drivers
  3. 2.3 DTIs for Injection Industry Opportunities and Challenges
  4. 2.4 DTIs for Injection Industry Restraints
3 DTIs for Injection Market by Manufacturers
  1. 3.1 Global DTIs for Injection Revenue by Manufacturers (2021-2026)
  2. 3.2 Global DTIs for Injection Sales by Manufacturers (2021-2026)
  3. 3.3 Global DTIs for Injection Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global DTIs for Injection Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global DTIs for Injection Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global DTIs for Injection Manufacturers, Product Type & Application
  7. 3.7 Global DTIs for Injection Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global DTIs for Injection Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 DTIs for Injection Players Market Share by Revenue in 2025
  11. 3.8.3 2025 DTIs for Injection Tier 1, Tier 2, and Tier 3
4 DTIs for Injection Market by Type
  1. 4.1 DTIs for Injection Type Introduction
  2. 4.1.1 Argatroban
  3. 4.1.2 Bivalirudin
  4. 4.1.3 Other
  5. 4.2 Global DTIs for Injection Sales by Type
  6. 4.2.1 Global DTIs for Injection Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global DTIs for Injection Sales by Type (2021-2032)
  8. 4.2.3 Global DTIs for Injection Sales Market Share by Type (2021-2032)
  9. 4.3 Global DTIs for Injection Revenue by Type
  10. 4.3.1 Global DTIs for Injection Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global DTIs for Injection Revenue by Type (2021-2032)
  12. 4.3.3 Global DTIs for Injection Revenue Market Share by Type (2021-2032)
5 DTIs for Injection Market by Application
  1. 5.1 DTIs for Injection Application Introduction
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global DTIs for Injection Sales by Application
  7. 5.2.1 Global DTIs for Injection Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global DTIs for Injection Sales by Application (2021-2032)
  9. 5.2.3 Global DTIs for Injection Sales Market Share by Application (2021-2032)
  10. 5.3 Global DTIs for Injection Revenue by Application
  11. 5.3.1 Global DTIs for Injection Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global DTIs for Injection Revenue by Application (2021-2032)
  13. 5.3.3 Global DTIs for Injection Revenue Market Share by Application (2021-2032)
6 Global DTIs for Injection Sales by Region
  1. 6.1 Global DTIs for Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global DTIs for Injection Sales by Region (2021-2032)
  3. 6.2.1 Global DTIs for Injection Sales by Region (2021-2026)
  4. 6.2.2 Global DTIs for Injection Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America DTIs for Injection Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe DTIs for Injection Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific DTIs for Injection Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa DTIs for Injection Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa DTIs for Injection Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global DTIs for Injection Revenue by Region
  1. 7.1 Global DTIs for Injection Revenue by Region
  2. 7.1.1 Global DTIs for Injection Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global DTIs for Injection Revenue by Region (2021-2026)
  4. 7.1.3 Global DTIs for Injection Revenue by Region (2027-2032)
  5. 7.1.4 Global DTIs for Injection Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America DTIs for Injection Revenue (2021-2032)
  8. 7.2.2 North America DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe DTIs for Injection Revenue (2021-2032)
  11. 7.3.2 Europe DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific DTIs for Injection Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa DTIs for Injection Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa DTIs for Injection Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Yangtze River Pharmaceutical
  2. 8.1.1 Yangtze River Pharmaceutical Company Information
  3. 8.1.2 Yangtze River Pharmaceutical Business Overview
  4. 8.1.3 Yangtze River Pharmaceutical DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Yangtze River Pharmaceutical DTIs for Injection Product Portfolio
  6. 8.1.5 Yangtze River Pharmaceutical Recent Developments
  7. 8.2 Beijing SL Pharmaceutical
  8. 8.2.1 Beijing SL Pharmaceutical Company Information
  9. 8.2.2 Beijing SL Pharmaceutical Business Overview
  10. 8.2.3 Beijing SL Pharmaceutical DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Beijing SL Pharmaceutical DTIs for Injection Product Portfolio
  12. 8.2.5 Beijing SL Pharmaceutical Recent Developments
  13. 8.3 CSPC Ouyi Pharmaceutical
  14. 8.3.1 CSPC Ouyi Pharmaceutical Company Information
  15. 8.3.2 CSPC Ouyi Pharmaceutical Business Overview
  16. 8.3.3 CSPC Ouyi Pharmaceutical DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CSPC Ouyi Pharmaceutical DTIs for Injection Product Portfolio
  18. 8.3.5 CSPC Ouyi Pharmaceutical Recent Developments
  19. 8.4 Lunan Pharmaceutical
  20. 8.4.1 Lunan Pharmaceutical Company Information
  21. 8.4.2 Lunan Pharmaceutical Business Overview
  22. 8.4.3 Lunan Pharmaceutical DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Lunan Pharmaceutical DTIs for Injection Product Portfolio
  24. 8.4.5 Lunan Pharmaceutical Recent Developments
  25. 8.5 BrightGene
  26. 8.5.1 BrightGene Company Information
  27. 8.5.2 BrightGene Business Overview
  28. 8.5.3 BrightGene DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BrightGene DTIs for Injection Product Portfolio
  30. 8.5.5 BrightGene Recent Developments
  31. 8.6 The Medicines Company
  32. 8.6.1 The Medicines Company Company Information
  33. 8.6.2 The Medicines Company Business Overview
  34. 8.6.3 The Medicines Company DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 The Medicines Company DTIs for Injection Product Portfolio
  36. 8.6.5 The Medicines Company Recent Developments
  37. 8.7 Teva Pharmaceutical
  38. 8.7.1 Teva Pharmaceutical Company Information
  39. 8.7.2 Teva Pharmaceutical Business Overview
  40. 8.7.3 Teva Pharmaceutical DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Teva Pharmaceutical DTIs for Injection Product Portfolio
  42. 8.7.5 Teva Pharmaceutical Recent Developments
  43. 8.8 Sandoz
  44. 8.8.1 Sandoz Company Information
  45. 8.8.2 Sandoz Business Overview
  46. 8.8.3 Sandoz DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sandoz DTIs for Injection Product Portfolio
  48. 8.8.5 Sandoz Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer DTIs for Injection Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Mitsubishi Tanabe Pharma
  56. 8.10.1 Mitsubishi Tanabe Pharma Company Information
  57. 8.10.2 Mitsubishi Tanabe Pharma Business Overview
  58. 8.10.3 Mitsubishi Tanabe Pharma DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Mitsubishi Tanabe Pharma DTIs for Injection Product Portfolio
  60. 8.10.5 Mitsubishi Tanabe Pharma Recent Developments
  61. 8.11 GlaxoSmithKline
  62. 8.11.1 GlaxoSmithKline Company Information
  63. 8.11.2 GlaxoSmithKline Business Overview
  64. 8.11.3 GlaxoSmithKline DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GlaxoSmithKline DTIs for Injection Product Portfolio
  66. 8.11.5 GlaxoSmithKline Recent Developments
  67. 8.12 Eugia Pharma
  68. 8.12.1 Eugia Pharma Company Information
  69. 8.12.2 Eugia Pharma Business Overview
  70. 8.12.3 Eugia Pharma DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Eugia Pharma DTIs for Injection Product Portfolio
  72. 8.12.5 Eugia Pharma Recent Developments
  73. 8.13 Dr.Reddy's Laboratories
  74. 8.13.1 Dr.Reddy's Laboratories Company Information
  75. 8.13.2 Dr.Reddy's Laboratories Business Overview
  76. 8.13.3 Dr.Reddy's Laboratories DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Dr.Reddy's Laboratories DTIs for Injection Product Portfolio
  78. 8.13.5 Dr.Reddy's Laboratories Recent Developments
  79. 8.14 Aurobindo Pharma
  80. 8.14.1 Aurobindo Pharma Company Information
  81. 8.14.2 Aurobindo Pharma Business Overview
  82. 8.14.3 Aurobindo Pharma DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Aurobindo Pharma DTIs for Injection Product Portfolio
  84. 8.14.5 Aurobindo Pharma Recent Developments
  85. 8.15 Apotex
  86. 8.15.1 Apotex Company Information
  87. 8.15.2 Apotex Business Overview
  88. 8.15.3 Apotex DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Apotex DTIs for Injection Product Portfolio
  90. 8.15.5 Apotex Recent Developments
  91. 8.16 Accord Healthcare
  92. 8.16.1 Accord Healthcare Company Information
  93. 8.16.2 Accord Healthcare Business Overview
  94. 8.16.3 Accord Healthcare DTIs for Injection Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Accord Healthcare DTIs for Injection Product Portfolio
  96. 8.16.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 DTIs for Injection Value Chain Analysis
  2. 9.1.1 DTIs for Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 DTIs for Injection Production Mode & Process
  6. 9.2 DTIs for Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 DTIs for Injection Distributors
  9. 9.2.3 DTIs for Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst